Figure 3. HNF-6 is required for proper morphology of the neuromuscular junction.
Image credit: Audouard, et.al. 2012 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! ALS ACT: Biomarker Discovery for ALS
Sponsor: The ALS Association, ALS Finding A Cure
Description: ALS Finding a Cure (ALS FAC), the ALS Association (ALSA) are pleased to announce a call for biomarker discovery projects. The call for proposals is open to academia and industry world-wide and is part of a broader initiative, the “ALS Biomarker Collaboration,“ encouraging the development of new ALS biomarkers in a pre-competitive space. Proposed projects should be completed over 12-18 months. Budget should not exceed $100,000.
Deadline: Letter of Intent due by January 8, 2018.



NEW! Rapid Isolation and Characterization of Extracellular Vesicles of CNS Origin
Sponsor: NIH Blueprint Neurotherapeutics Network
Description: This Funding Opportunity Announcement (FOA) encourages applications that will develop novel technologies and/or tools for the isolation and characterization of extracellular vesicles (EVs) of Central Nervous System (CNS) origin. The primary focus of the technology development includes robust and reproducible CNS-EV isolation methods. Specifically, there is a need to establish technologies for the isolation and purification of CNS-EVs from peripheral samples and the characterization of CNS-EV types, cargos, and origin, as well as to validate these methods for further analyses. Validation of these technologies may include the analysis of the full range of EV composition such as RNA, proteins, lipids, and metabolites.
Deadline: Application due by January 22, 2018.



NEW! ALS Research Grants
Sponsor: Thierry-Latran Foundation
Description: The Thierry-Latran Foundation is pleased to announce the opening of its 10th call for ALS projects, based in Europe and Horizon 2020 Third Countries, for a total amount up to € 400 000.
Deadline: Abstract due by January 29, 2018.



NEW! Joint Call for European Research Projects on Rare Diseases
Sponsor: ERA-Net “E-Rare”
Description: The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear translational research approach. Projects shall involve a group of rare diseases or a single rare disease affecting not more than five in 10 000 persons in the European Community, EC associated states and Canada - including ALS. The research projects have to focus on hypothesis-driven use of multi-omic integrated approaches for discovery of disease causes and/or functional validation in the context of rare diseases.
Deadline: Pre-Proposal due by February 6, 2018.



NEW! Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases
Sponsor: NINDS
Description: The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients. Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials. The studies supported through this FOA should be clinical observational studies. No interventional studies will be supported via this funding mechanism.
Deadline: Application due by February 15, 2018.



NEW! Klingenstein-Simons Fellowship Awards in Neuroscience
Sponsor: The Esther A. and Joseph Klingenstein Fund
Description: The Klingenstein-Simons Fellowship Awards in the Neurosciences supports, in the early stages of their careers, young investigators engaged in basic or clinical research that may lead to a better understanding of neurological and psychiatric disorders. The award of $225,000 is payable over a three-year period. To qualify, researchers must have a tenure-track appointment or the equivalent and be based in the US.
Deadline: Application due by February 15, 2018.



NEW! Transformational Research: Canada 2018
Sponsor: Weston Brain Institute
Description: This program funds transformative, novel, high-risk, high-reward translational research projects with excellent preliminary data aimed at accelerating the development of therapies for neurodegenerative diseases of aging including FTD. A maximum of $1,500,000 over up to 3 years per project. PIs must be at or above the level of Assistant Professor or equivalent, work in Canada at least 30% of the time, and be affiliated with a CRA-qualified institution.
Deadline: February 15, 2018 (extended).



Altman Award in Developmental Neuroscience (Worldwide)
Sponsor: Japan Neuroscience Society
Description: This award focuses on developmental neuroscience at the cellular and/or tissue level. Projects recognized include adult neurogenesis and its biological significance and its changes resulting from aging and diseases. The award is $10,000 USD. Researchers worldwide are invited to apply. Applicants must hold a PhD for no more than 20 years. Applications accepted beginning November 1, 2017.
Deadline: Application due by January 31, 2018.



High Impact Neuroscience Research Resource Grants
Sponsor: NINDS
Description: This funding opportunity announcement (FOA) supports high impact efforts to make resources available to neuroscience researchers. Projects should engage in one or more of the following activities: facilitating access to cutting edge reagents or techniques, dissemination of resources to new user groups, or innovative approaches to increase the scale/efficiency of resource production and delivery. Applications focused primarily on technology or software development are not responsive to this FOA, as the focus is on dissemination or provision of resources. Use of existing technologies to develop new reagents or genetic lines of significant value to the research community may be appropriate. Projects should address compelling needs of broad communities of neuroscience researchers or should offer unique services that otherwise would be unavailable.
Deadline: Application due by February 9, 2018.



Rapid Response: Canada 2018
Sponsor: Weston Brain Institute
Description: This program provides seed funding for high-risk, high-reward, translational research projects on neurodegenerative diseases of aging including FTD.   A maximum of $200,000 over up to 18 months per project. Principal applicants must be researchers working in Canada at least 30% of the time above the level of Postdoctoral Fellow, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Applications are expected to begin to be accepted in February 2018.
Deadline: Letter of Intent due by April 2018.



Rapid Response: Ireland, Netherlands, UK 2018
Sponsor: Weston Brain Institute
Description: Provides seed funding up to £175,000 per project for over up to 2 years for novel, high-risk, high-reward translational research projects that accelerate the development of therapeutics for neurodegenerative diseases of aging including FTD based in Europe. Applications will begin to be accepted in January 2018.
Deadline: Application due by April 2018.



Research Grants
Sponsor: Fight MND
Description: These grants support the preclinical research, development, and assessment of therapeutics for MND through to (and including) completion of Phase I clinical trials. These grants are each awarded with an offer of up to AUD $1,000,000 in support available for 3-year projects. Researchers globally are invited to apply.
Deadline: Application due by April 1, 2018.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications will be accepted on a rolling basis.



Identify, Analyze and Evaluate Potential Risk Factors for ALS
Sponsor: CDC
Description: The purpose of this funding opportunity announcement (FOA) is to allow for investigator initiated research that will further the understanding of potential risk factors for ALS, while supporting the National ALS Registry's mission. Maximum award is $400,000 USD. Note: This is a forecasted opportunity.
Deadline: February 16, 2018 (estimated).



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail